PMGC HOLDINGS INC

ELABNASDAQ

🏆 #3887 by market capUS Equity

$207.84▲ $2.27 (+1.09%)

Simulated price

1h—

24h▲ 1.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$4M

Small Cap

📈Revenue Growth (YoY)

+141.1%

High Growth

📊Gross Margin

32.7%

Moderate

💵FCF Margin

—

⚖️P/S Ratio

3.3x

Fair

Otter Score

Weak

No chart data available for ELAB.

Trading Snapshot

Day Range: $207.11 – $209.60
52-Week Range: $0.84 – $309.12
Volume: $2.44B
Avg Volume: $2.47B
Shares Outstanding: 4.5M
Next Earnings: Oct 26, 2026

Fundamentals Snapshot

Annual Revenue: $590,084
Last Q Revenue: $681,994
P/E Ratio: —
P/S Ratio: 3.3x
EPS (TTM): $-245.60
Dividend Yield: —

Why Investors Own ELAB

✓High-growth profile — revenue up +42.8% YoY with expanding US Equity exposure.
✓Healthy economics — 76% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$590,084▲ +43.2% YoY

Gross Margin (TTM)

76.2%▲ +1.4% YoY

Operating Income (TTM)

$113,886▲ +43.2% YoY

Free Cash Flow (TTM)

$145,751▲ +43.2% YoY

About PMGC HOLDINGS INC

PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.

🦦